Ketamine: new uses for an old drug

Granry, J.C.; Dubé, Laurent; Turroques, Hélène; Conreux, F.

doi:10.1097/00001503-200006000-00011

Cited by 23 publications

(6 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Pediatric intestinal biopsy procedures with pharyngeal introduction of a wire‐guided metal capsule require sedation or even general anesthesia, particularly in young children. In the hands of an experienced anesthesia team, a combination of racemic ketamine and midazolam is considered to provide safe and effective sedation for various diagnostic and therapeutic short‐term procedures in children (1–6). However, despite two recent follow‐up studies (2,7), problems before and after discharge from the hospital of children given low‐dose sedation with ketamine and midazolam do not seem to have been well followed up.…”

Section: Introductionmentioning

confidence: 99%

Sedation with ketamine and low‐dose midazolam for short‐term procedures requiring pharyngeal manipulation in young children

Novak¹,

Åkeson

Åkeson³

2007

Pediatric Anesthesia

View full text Add to dashboard Cite

Careful titration of ketamine and low-dose midazolam provides adequate sedation for nonsurgical pediatric short-term procedures also requiring considerable pharyngeal manipulation, particularly considering the low number of serious airway problems such as laryngospasm. The high incidence of late postoperative problems suggests that prospective studies should be designed for long-term follow-up of young children subjected to sedation or anesthesia.

show abstract

Section: Introductionmentioning

confidence: 99%

Sedation with ketamine and low‐dose midazolam for short‐term procedures requiring pharyngeal manipulation in young children

Novak¹,

Åkeson

Åkeson³

2007

Pediatric Anesthesia

View full text Add to dashboard Cite

show abstract

“…Temporary respiratory depression and apnoea have been reported after intravenous bolus administration of ketamine due to increased concentrations of the drug in the central nervous system. 23 In our study, we did not observe transient apnoea or respiratory depression, as we were careful to administer ketamine over 30 to 60 seconds.…”

Section: Discussionmentioning

confidence: 59%

Randomised, cross-over comparison of sevoflurane and ketamine-midazolam anaesthesia in children undergoing extracorporeal shock-wave lithotripsy

et al. 2008

View full text Add to dashboard Cite

show abstract

“…44 Pharmacodynamic properties of ketamine and its metabolites control glutamatergic excitatory responses by antagonizing NMDARs, 48,49 and it has been tested as a promising antidepressant therapy. 50,51 Ketamine in subanesthetic doses is able to block NMDARs in INs. The increased release of glutamate allows more intense binding of the neurotransmitter to α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptors (AMPARs), thus promoting quickly sodium and potassium permeability, and the activation of voltagegated calcium channels (VGCCs).…”

Section: Rapid Action Antidepressants: Ketamine As a Novel Treatment ...mentioning

confidence: 99%

The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus

Barrutieta-Arberas,

Ortuzar,

Vaquero-Rodríguez

et al. 2023

Exp Biol Med (Maywood)

View full text Add to dashboard Cite

Major depressive disorder (MDD) is a complex illness that is arising as a growing public health concern. Although several brain areas are related to this type of disorders, at the cellular level, the parvalbumin-positive cells of the hippocampus interplay a very relevant role. They control pyramidal cell bursts, neuronal networks, basic microcircuit functions, and other complex neuronal tasks involved in mood disorders. In resistant depressions, the efficacy of current antidepressant treatments drops dramatically, so the new rapid-acting antidepressants (RAADs) are being postulated as novel treatments. Ketamine at subanesthetic doses and its derivative metabolites have been proposed as RAADs due to their rapid and sustained action by blocking N-methyl-d-aspartate (NMDA) receptors, which in turn lead to the release of brain-derived neurotrophic factor (BDNF). This mechanism produces a rapid plasticity activation mediated by neurotransmitter homeostasis, synapse recovery, and increased dendritic spines and therefore, it is a promising therapeutic approach to improve cognitive symptoms in MDD.

show abstract

Ketamine: new uses for an old drug

Cited by 23 publications

References 27 publications

Sedation with ketamine and low‐dose midazolam for short‐term procedures requiring pharyngeal manipulation in young children

Sedation with ketamine and low‐dose midazolam for short‐term procedures requiring pharyngeal manipulation in young children

Randomised, cross-over comparison of sevoflurane and ketamine-midazolam anaesthesia in children undergoing extracorporeal shock-wave lithotripsy

The role of ketamine in major depressive disorders: Effects on parvalbumin-positive interneurons in hippocampus

Contact Info

Product

Resources

About